Brimonidine 0.15% effective adjunctive therapy for open-angle glaucoma, ocular hypertension
September 1st 2006Fort Lauderdale, FL-Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P, Allergan) is an effective adjunctive therapy in patients with glaucoma using latanoprost (Xalatan, Pfizer Ophthalmics) who require additional IOP lowering, according to research reported at the Association for Research in Vision and Ophthalmology annual meeting.
Modified glaucoma value reduces outflow resistance
September 1st 2006Fort Lauderdale, FL-A modified glaucoma valve made of a porous polymer material reduced outflow resistance in tests conducted in an animal model. The reduced resistance should in turn result in improved control of IOP over conventional implants, explained R. Rand Allingham, MD, at the annual meeting of the Association for Research in Vision and Ophthalmology.
Study finds ethnic-related differences in CSLO parameters
September 1st 2006Fort Lauderdale, FL-Significant differences in optic disc topography exist between ethnic groups, according to the results of a study analyzing parameters measured with confocal scanning laser ophthalmoscopy (CSLO) among subjects with European, subcontinent Indian, and African-American ancestries.
ECP probe tip placement key for optimal energy delivery
September 1st 2006Fort Lauderdale, FL-Surgeons performing endoscopic cyclophotocoagulation (ECP) to treat glaucoma should take careful note of probe position in order to optimize the treatment, said Malik Kahook, MD, at the annual meeting of the Association for Research in Vision and Ophthalmology.
Absence of preservative linked with less toxicity in study
September 1st 2006Fort Lauderdale, FL-A study that compared the toxicity of two antiglaucoma drugs, travoprost 0.004% (Travatan, Alcon Laboratories) without the preservative benzalkonium chloride with that of latanoprost 0.005% (Xalatan, Pfizer) with 0.02% benzalkonium chloride, found that the absence of the preserving agent was associated with significantly less toxicity in immortalized human corneal epithelial cells, reported Richard W. Yee, MD, at the annual meeting of the Association for Research in Vision and Ophthalmology.
SLT may be useful as primary glaucoma therapy
September 1st 2006London, Ontario-During at least the first 12 months after treatment initiation, selective laser trabeculoplasty (SLT) and latanoprost 0.005% (Xalatan, Pfizer) are associated with equivalent efficacy and safety profiles when used as primary therapy for newly diagnosed open-angle glaucoma or ocular hypertension, according to the results of a prospective, multicenter, parallel comparison, clinical trial conducted by researchers at Ivey Eye Institute, University of Western Ontario, London.
Fixed-combination therapy has greater IOP-lowering effect
September 1st 2006Charleston, SC-The brimonidine 0.2%/ timolol 0.5% fixed combination (Combigan, Allergan) administered twice daily is as effective as the concurrent use of brimonidine and timolol and is significantly more effective than monotherapy with either brimonidine three times daily or timolol twice daily, according to E. Randy Craven, MD, who presented his results at the American Glaucoma Society meeting here. The fixed combination is also superior to brimonidine monotherapy in long-term safety and the development of fewer ocular allergies, Dr. Craven said.
Use positive approach when discussing glaucoma diagnosis
September 1st 2006San Francisco-Ophthalmologists should always strive to emphasize the success of treatment when discussing glaucoma with their patients, said Reay H. Brown, MD, at glaucoma subspecialty day during the American Society of Cataract and Refractive annual meeting.
Electrocautery device helps improve OAG management
September 1st 2006Fort Lauderdale, FL-The Trabectome procedure (NeoMedix Corp.) with its low complication rate and high success rate suggests that it might be a promising primary surgical intervention for improved surgical management of patients with open-angle glaucoma (OAG), according to Sameh Mosaed, MD, at the annual meeting of the Association for Research in Vision and Ophthalmology here.
Techniques offer similar sensitivity, specificity
September 1st 2006Fort Lauderdale, FL-Multifocal visual evoked potentials (mfVEP) and standard automated perimetry (SAP) perform in a similar manner in eyes with high-risk ocular hypertension or early glaucoma, according to a comparison study. However, agreement between the two techniques reached only 80%, suggesting that they detect different defects in some cases, said Brad Fortune, OD, PhD, associate scientist, Discoveries in Sight, Devers Eye Institute, Portland, OR.
Dr. Wafapoor joins staff at Retina Health Center
September 1st 2006Fort Myers, FL-Retina Health Center is pleased to announce the addition of Hussein Wafapoor, MD, to the staff of its Fort Myers and Naples, FL, offices. Dr. Wafapoor brings extensive experience in the treatment of retinal disorders, particularly diabetic retinopathy and age-related macular degeneration.
Book helps kids prepare for eye surgery
August 15th 2006As a pediatric ophthalmologist, Mark Silverberg, MD, relies on special tactics and tools to make his young patients feel at ease. Dr. Silverberg is pleased to have a new book to share with kids and their families that tells the story of eye surgery from a child's perspective, in simple terms with illustrative photographs.
Transitions Online Marketing materials available in Spanish
August 15th 2006Pinellas Park, FL-Transitions Optical Inc. continues to spread the word about the importance of protecting eyes from ultraviolet (UV) radiation with an expanded consumer initiative geared toward the rising Hispanic-origin population in the United States.
Should CTRs be implanted in every patient with PXE?
August 15th 2006Cataract surgery in the presence of pseudoexfoliation of the lens (PXE) presents surgeons with many challenges. In addition to a higher incidence of glaucoma, these patients have loss of zonular integrity, occasionally associated with lens subluxation and pupils that dilate poorly.